S. Gross

Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)

L. Schwartz, W. Hayes, S. Dimitrijević, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial

T. Graubert, C. Corless, T. George, 2010 .

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

G. Giaccone, F. Cappuzzo, F. Shepherd, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus

R. Boellaard, G. Giaccone, Roman K. Thomas, 2009, Journal of Nuclear Medicine.

A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)

G. Giaccone, F. Cappuzzo, F. Shepherd, 2007 .

Pharmacodynamics of RAD001 measured by early FDG PET in patients with recurrent NSCLC

G. Giaccone, Roman K. Thomas, T. Zander, 2008 .

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

G. Giaccone, F. Shepherd, L. Crinò, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.